As a result, the Food and Drug Administration (FDA) approved the use of selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene in women with a 5-year BCRAT risk of 1.67% or greater, based on the average 5-year breast cancer risk for a 50-year-old white female7,19,20. This evidence concerns the gene ESR1 and breast carcinoma.